Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Tavernier, 2007, Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial., Leukemia, 21, 1907, 10.1038/sj.leu.2404824 Oriol, 2010, Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group., Haematologica, 95, 589, 10.3324/haematol.2009.014274 Fielding, 2007, Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study., Blood, 109, 944, 10.1182/blood-2006-05-018192 Kantarjian, 2010, Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration., Cancer, 116, 5568, 10.1002/cncr.25354 Gökbuget, 2012, Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation., Blood, 120, 2032, 10.1182/blood-2011-12-399287 Nagorsen, 2011, Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab., Exp Cell Res, 317, 1255, 10.1016/j.yexcr.2011.03.010 Topp, 2014, Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia., J Clin Oncol, 32, 4134, 10.1200/JCO.2014.56.3247 Topp, 2015, Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study., Lancet Oncol, 16, 57, 10.1016/S1470-2045(14)71170-2 Topp, 2011, Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival., J Clin Oncol, 29, 2493, 10.1200/JCO.2010.32.7270 National Cancer Institute, NCI common terminology criteria for adverse events (CTCAE) v4.0. Bargou, 2008, Tumor regression in cancer patients by very low doses of a T cell-engaging antibody., Science, 321, 974, 10.1126/science.1158545 Simon, 1984, A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias., Stat Med, 3, 35, 10.1002/sim.4780030106 Kantarjian, 2013, Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia., Cancer, 119, 2728, 10.1002/cncr.28136 Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia., Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226 Topp, 2015, Re-exposure to blinatumomab after CD19-positive relapse: experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL) [abstract]., J Clin Oncol, 33